Real-world outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia treated with ponatinib – final 6-year results from a Belgian registry

Real-world outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia treated with ponatinib – final 6-year results from a Belgian registry

Background: Ponatinib is a third-generation tyrosine kinase inhibitor (TKI) for treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in patients who fail or are intolerant to a second generation TKI or who carry the T315I mutation....

Full description

Saved in:
Bibliographic Details
Main Authors: Timothy Devos, Dries Deeren, Koen Theunissen, Dominik Selleslag, Benjamin Bailly, Violaine Havelange, Philippe Lewalle, Stef Meers, Fleur Samantha Benghiat, Alain Gadisseur, Nikki Granacher, Gaëtan Vanstraelen, Hélène Vellemans, Ann De Becker, Mia Janssen, Inge Vrelust, Marie Lejeune, Ann Van de Velde, Agnès Triffet, Michael Beck, Hinde Sebti, Dominiek Mazure
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Hematology
Subjects:
Ponatinib
real-world evidence
registry
Philadelphia chromosome-positive acute lymphoblastic leukemia
chronic myeloid leukemia
Online Access:https://www.tandfonline.com/doi/10.1080/16078454.2025.2534196
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/16078454.2025.2534196

Similar Items